EAU 2024 Bladder Cancer

REVIEW UroToday

Viewing 1-20 of 39 articles

EAU 2024: Membranous NECTIN-4 Expression in Metastasis Versus Matched Primary Tumor More Accurately Predicts Enfortumab Vedotin Response

EAU 2024: First-Line Maintenance Therapy in Patients with Locally Advanced or Metastatic Urothelial Carcinoma in Routine Care in Germany: Preliminary Results of the Prospective CARAT-UBC Registry

EAU 2024: TiP: Phase 3 Study of Disitamab Vedotin with Pembrolizumab Versus Chemotherapy in Patients with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma That Expresses HER2 (DV-001)

EAU 2024: Pembrolizumab in BCG Refractory Non-Muscle Invasive Bladder Cancer is Associated with High Rates of Adverse Events and Discontinuation of Treatment

EAU 2024: State-of-the-Art Lecture: New Standard Treatment for Metastatic Bladder Cancer Based on EV-302/KEYNOTE-A39

EAU 2024: Photodynamic Diagnosis (PDD) Directed Biopsies vs White Light Bladder Mapping in Patients with Positive Cytology and Negative Preoperative Workup: An International Multicenter Retrospective Study

EAU 2024: First Results of NURE-Combo: A Phase 2 Study of Neoadjuvant Nivolumab Nab-Paclitaxel Followed by Postsurgical Adjuvant Nivolumab in Patients with Muscle-Invasive Bladder Cancer

EAU 2024: A Prospective, Comparative, Within-Patient Controlled Multicenter Phase III Study Comparing Blue Light Cystoscopy Versus White Light Cystoscopy for the Detection of Bladder Cancer Using Modern HD 4K Equipment

EAU 2024: Non-Thermal Atmospheric Plasma Ablation for Intermediate Risk Non-Muscle Invasive Bladder Cancer: A First in Human Trial

EAU 2024: Is There a Role for BCG in Very High-Risk Non-Muscle Invasive Bladder Carcinoma? Multicenter Analysis of Oncological Outcomes and Risk Dynamics

EAU 2024: Subsequent Therapies After Intravesical BCG in Patients with Bladder Cancer: Analysis of Real-World Treatment Patterns

EAU 2024: Intravesical Administration of Durvalumab to Patients with High Risk Non-Muscle Invasive Bladder Cancer Who Experience BCG Failure. Final Results from a Phase II Study by the Hellenic GU Cancer Group

EAU 2024: The International Bladder Cancer Group Intermediate-Risk Non-Muscle Invasive Bladder Cancer (IBCG IR-NMIBC) Scoring System Predicts the Need for Intervention for Patients on Active Surveillance

EAU 2024: Does Audit, Feedback and Education Improve Quality Indicator Achievement and Reduce Early Recurrence Rates in TURBT Surgery for NMIBC? Results from the RESECT Cluster Randomised Trial

EAU 2024: First Results of the Phase Ib-II BladderGATE Clinical Trial: Intravenous Atezolizumab + Intravesical Bacillus Calmette-Guérin (BCG) Upfront Combination in BCG-Naïve High Risk Non-Muscle Invasive Bladder Cancer Patients

EAU 2024: Outpatient Laser Coagulation of Low-Grade Intermediate Risk Bladder Tumor Compared with TURBT, 12 Months and Long-Term Follow-up of a Noninferiority RCT

EAU 2024: A Phase II Clinical Trial of Neoadjuvant Sasanlimab and Stereotactic Body Radiation Therapy as an in Situ Vaccine for Cisplatin Ineligible Muscle Invasive Bladder Cancer

EAU 2024: Challenging the Paradigm of BCG Unresponsive Bladder Cancer: Does Additional BCG Have an Effect?

EAU 2024: Efficacy of Intravesical Nadofaragene Firadenovec-Vncg for Patients with BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: 36-Month Follow-up from a Phase 3 Trial

EAU 2024: First Safety and Efficacy Results of the TAR-210 Erdafitinib Intravesical Delivery System in Patients with Non–muscle-Invasive Bladder Cancer with Select FGFR Alterations

1
2